Menu

Home / For Visitors / 2025 Exhibitor Product / Therapeutic humanized anti-CD24 monoclonal antibody

Therapeutic humanized anti-CD24 monoclonal antibody

Model: HH0146

Category: Pharmaceutical

Exhibitor: CHINA MEDICAL UNIVERSITY

Booth No: N116

Characteristic

The humanized monoclonal antibody HH0146, successfully developed by our team, possesses a unique anti-cancer mechanism that "reverses the tumor immunosuppressive microenvironment," achieving highly effective anti-tumor effects. Its anti-cancer mechanism has four key features:
1. Enhances macrophage phagocytic activity by 10 times.
2. Increases natural killer cell cytotoxicity against cancer cells by 3 times.
3. Achieves a tumor suppression rate of >95% in CD24-positive triple-negative breast cancer.
4. Demonstrates an 80% improvement in survival rate in animal studies.

Other Products

NuPlus: The First-in-Class, LNP-Encapsulated, Non-Coding Oligonucleotide Targeting DDB2 for Intravenous Treatment of Metastatic TNBC

Products you may be interested in

Highest Rated Products

TOP